Clinical Trial Update: Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating disitamab vedotin combined with tislelizumab and capecitabine as perioperative treatment for locally advanced, HER2-positive gastric ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Disitamab Vedotin (disitamab vedotin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: RECRUITING